GSK Patient Assistance Program Will Cover Newly Approved Tykerb
This article was originally published in The Pink Sheet Daily
Executive Summary
Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.
You may also be interested in...
GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer
Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.
GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer
Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.
National Cancer Institute Kicks Off Head-To-Head Tykerb vs. Herceptin Study
Enrollment could exceed global targets, principal investigator tells “The Pink Sheet” Daily.